Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Mohammad Azab bought 15,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was bought at an average price of $2.22 per share, with a total value of $33,300.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
Mohammad Azab also recently made the following trade(s):
- On Friday, September 22nd, Mohammad Azab purchased 10,000 shares of Xenon Pharmaceuticals stock. The shares were acquired at an average price of $2.95 per share, with a total value of $29,500.00.
- On Friday, August 18th, Mohammad Azab purchased 6,335 shares of Xenon Pharmaceuticals stock. The shares were acquired at an average price of $2.90 per share, with a total value of $18,371.50.
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded up $0.05 during midday trading on Monday, hitting $2.35. The company had a trading volume of 44,884 shares, compared to its average volume of 92,114. Xenon Pharmaceuticals Inc. has a 52 week low of $2.10 and a 52 week high of $9.95.
Separately, Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Xenon Pharmaceuticals by 90.1% in the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after purchasing an additional 102,890 shares during the period. KCG Holdings Inc. purchased a new position in Xenon Pharmaceuticals in the 1st quarter worth approximately $122,000. K2 Principal Fund L.P. increased its stake in Xenon Pharmaceuticals by 40.6% in the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 47,535 shares during the period. DAFNA Capital Management LLC increased its stake in Xenon Pharmaceuticals by 11.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after purchasing an additional 38,081 shares during the period. Finally, Scotia Capital Inc. increased its stake in Xenon Pharmaceuticals by 36.0% in the 2nd quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 9,426 shares during the period. 54.75% of the stock is currently owned by institutional investors.
WARNING: “Insider Buying: Xenon Pharmaceuticals Inc. (XENE) Director Purchases 15,000 Shares of Stock” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/04/mohammad-azab-buys-15000-shares-of-xenon-pharmaceuticals-inc-xene-stock.html.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.